The TEAM Approach to Improving Oncology Outcomes by Incorporating Palliative Care in Practice by Bakitas, Marie A. et al.
University of Alabama at Birmingham, AL;
Partners–Massachusetts General
Hospital, Boston, MA; City of Hope Medical
Center, Duarte, CA; New York University
School of Medicine, New York, NY;
University of East Anglia, Norwich; Kings
College London, London, United Kingdom;
Princess Margaret Cancer Centre,
University Health Network, Toronto,
Ontario, Canada; and Johns Hopkins
University, Baltimore, MD
ASSOCIATED CONTENT
See accompanying commentary
on page 567
DOI: https://doi.org/10.1200/JOP.
2017.022939
The TEAM Approach to Improving
Oncology Outcomes by
Incorporating Palliative Care
in Practice
Marie A. Bakitas, Areej El-Jawahri, Morag Farquhar, Betty Ferrell, Corita Grudzen, Irene
Higginson, Jennifer S. Temel, Camilla Zimmermann, and Thomas J. Smith
Abstract
Palliative care (PC) concurrentwith usual oncology care is now the standard of care that is
recommended for any patient with advanced cancer to begin within 8 weeks of diagnosis
on the basis of evidence-driven national clinical practice guidelines; however, there are
not enough interdisciplinary palliative care teams to provide such care. How andwhat can
an oncology ofﬁce incorporate into usual care, borrowing the tools used in PC randomized
clinical trials (RCTs), to improve care for patients and their caregivers? We reviewed
the multiple RCTs for common practical elements and identiﬁed methods and techniques
that oncologists can use to deliver some parts of concurrent interdisciplinary PC. We
recommend the standardized assessment of patient-reported outcomes, including the
evaluation of symptoms with such tools as the Edmonton or Memorial Symptom
Assessment Scales, spirituality with the FICA Spiritual History Tool or similar questions,
and psychosocial distress with the Distress Thermometer. All patients should be assessed
for how they prefer to receive information, their current understanding of their situation,
and if they have considered some advance care planning. Approximately 1 hour of
additional time with the patient is required each month. If the oncologist does not have
established ties with spiritual care and social work, he or she should establish these
relationships for counseling as required. Caregivers should be asked about coping and
support needs. Oncologists can adapt PC techniques to achieve results that are similar to
those in theRCTs of PCplus usual care comparedwith usual care alone. This is comparable
to using data from RCTs of trastuzamab or placebo, adopting what was used in the RCTs
without modiﬁcation or dilution.
INTRODUCTION
The benefits of structured, team-based, mul-
tidisciplinary palliative care (PC) concurrent
with usual oncology care have now been
demonstrated in multiple randomized
trials in situations from metastatic lung
cancer to hematopoietic stem cell trans-
plantation. These benefits typically include
better quality of life and symptom control,
less anxiety and depression, greater prog-
nostic awareness, less caregiver distress,
equal or better survival, and equal or lower
costs. (Table 1) These data are so com-
pelling that ASCOhas stated explicitly that
“every patientwith advanced cancer should
be seen by a PC interdisciplinary team
within 8weeks of diagnosis—establishing a
new standard of care.”20
The data that demonstrate the superiority
of PC are derived from trials that compared
concurrent PC plus usual oncology care
with usual oncology care alone—and usual
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Table 1. Summary of Recent Studies Comparing Usual Care With Usual Care Plus Palliative Care
Study and Population
Patient Experience
CostQOL Symptoms
Anxiety
Depression Caregiver Distress Survival
Brumley et al, 2007
(1/3 Ca)1
NM, satisfaction
increased
NM NM NM 5 2$7,550 per person, P 5 .03
More likely to die at home, less
likely to visit ED or be admitted
to hospice
Gade et al, 2008
(1/3 Ca)2
1, P 5 .04 NM NM NM 5 2$4,885 per person, P 5 .001;
fewer ICU admissions, P 5 .04;
longer hospice stays, P 5 .04
Bakitas et al, 2009
(Ca)3
1, P 5 .02 1, P 5 .06 Less
depressed
mood,
P 5 .02
Longer, 5.5
months;
P 5 .14 NS
5
Temel et al, 2010
(lung Ca)4
1, P 5 .03 7 lung cancer–specific
symptoms better
Less
depression,
P 5 .01
Longer, 2.7
months;
P 5 .02
Total cost was higher because
patients lived longer, but cost
per day was $117 lower5
Farquhar et al, 2014
(Ca as cause of
breathlessness)6
1 Reduced patient
distress due to
breathlessness,
P 5 .049
NM 5 5 5 Total costs £354 ($444) less;
better QOL; dominates cost-
effectiveness
Zimmermann et al,
2014 (Ca)7
1, P 5 .05 = at 3 months, P = .33 NM Better satisfaction
with care, P 5 .007;
= QOL8
5 NR
1 at 4 months, P = .05
Higginson et al, 2014
(dyspnea, most Ca)9
5 1 Mastery of
breathlessness,
P 5 .048;
Dyspnea 5
5 NR 5 5
Bakitas et al, 2015
(Ca)10,11
5, P 5 .30 5, P 5 .09 Mood 5 Lower depression and
stress, P 5 .02 and
.01, but not QOL
Longer,
6.5 months;
1-year OS,
63% v 48%;
P 5 .038
NR; equal resource use
Ferrell et al, 2015
(lung Ca)12,13
1, P , .001 1, P , .001 1, P , .001 1; better well-being and
less distress, P 5 .001;
less burden, P 5 .008
Longer,
6 months; NS
NR; more ADs, 44% v 9%,
P , .001
Grudzen et al, 2016
(patients with Ca in
ED)14
1, P 5 .03 ND 5 ND Longer, 5.2
months; NS,
P 5 .20
5; note only 25%-28% use of
hospice in both groups
Temel et al, 2016
(lung, GI Ca)15
5 at week 12, P 5 .34;
1 at week 24,
P 5 .01
NR 1, P 5 .048 116 Too early to tell NR; more likely to discuss EOL
wishes, 30% v 14.5%;
P 5 .004
El-Jawahri et al, 2016
(BMT)17
1 (smaller decrease),
P 5 .045
Less,P, .03at2weeks;
5 at 3 months
Less, P , .001 No change in QOL or anxiety;
less depression, P5 .0318
Too early to tell NR
Maltoni et al, 2016
(pancreas Ca)19
1, P 5 .04 NR; FACT-Hep, HCS,
and TOI all better
with PC
5 5 5; 1-year OS,
32%-37%
NR; improvements in use of
chemotherapy in the last
30 days, hospice LOS, place
of death
Abbreviations: +, improved; =, equal; AD, advance directive; BMT, bonemarrow transplant; Ca, cancer; ED, emergency department; EOL, end of life; FACT-Hep,
Functional Assessment of Cancer Therapy–Hepatobiliary; HCS,Hepatobiliary Cancer Subscale; LOS, length of stay; ND, not determined;NM, notmeasured; NR,
not reported; NS, not significant; OS, overall survival; PC, palliative care; QOL, quality of life; TOI, Trial Outcome Index.
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oncology care alone was bested in all trials. There are ongoing
trials to establish whether primary PC that is delivered by the
oncology team alone is equal to specialty palliative care. The
hypothesis of most of these trials is that oncology teams can do
muchof thework of specialty palliative care if the same tools and
approaches are used that the concurrent PC teams use in clinical
trials. Unlesswe use the same components of PC that are used in
trials, usual oncology care remainsusual oncology care, aswould
happen if the oncologist modified R-CHOP (rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone)
by leaving out vincristine and reducing the dose of cyclo-
phosphamide by 50%.
What, then, is in the PC care team toolkit and how can
oncologists adopt these techniques today in their practices?
THE TEAM APPROACH TO PC CONCURRENT WITH
USUAL ONCOLOGY CARE
The TEAM approach (Time, Education, Assessment, and
Management) components that have been distilled from clinical
trialsare listed inTable 2 andmake it patient and family centered,
education centered, and symptomcentered.We include here the
methods that were used in trials of an interdisciplinary team
approach to concurrent PC or, in the case of Massachusetts
General Hospital studies, an expert advance practice nurse or
doctor backed by an interdisciplinary team if needed.
Time dedicated to identifying the patients’ understanding
of their illness, treatment, and prognosis was a consistent
factor in the success of all PC randomized clinical trials. Such
discussions can take an extra hour per month22,23 andmay be
coordinated by oncologists, possibly with the assistance of
other team members—for example, an advanced practice
nurse or social worker. All important aspects of a PC visit
cannot be addressed by an oncologist in a 20-minute visit that
concentrates on the response to chemotherapy. These visits
can be in person or by phone or telemedicine, but an un-
derlying principle is that the visit must be structured and take
at least 1 hour per month. Most trials have included on the
teamPCadvancedpractice nurses anddoctorswhoare trained
in PC, as we do in most of our practices.
Education was a component of all clinical trials. In the
monthly visits with the PC team, patients and families can
explore realistic options. Structured topics should include the
identificationofpatients’ specific care goals, values and how to
perform value-derived treatment and advance care planning
decision-making. Prognostic awareness—understanding the
nature of their condition as a life-limiting illness—seems to be
key and requires coaching and direct communication by the
health care provider. More than two thirds of patients with
lung and colorectal cancer thought their palliative chemo-
therapy,24 radiation,25 and/or surgery26 could cure them. An
excellent communication guide—a manual to help prac-
titioners increase prognostic awareness—is highly recom-
mended.27 We have listed the important domains that are
usually covered in Table 3.
The value of education is that patients with prognostic
awareness, especially if advance medical directives were
completedmore than 30 days before death, die less often in the
hospital (19% v 50% in Australia28) and usemore hospice care
and for longer duration.29 In a non–small-cell lung cancer trial
by Temel, those in the PC group with greater prognostic
awareness received intravenous chemotherapy near the end of
life (EOL; ineffective fourth-line and fifth-line treatment30;
chemotherapy 9% of the time v 50% in the usual care group).
Those who have EOL discussions—goals of care and/or
understanding of illness—are more likely to be satisfied, to
die at the place of their choosing, and to have less distressed
relatives31; however, we, as their oncologists, must start these
conversations as people rarely bring it up themselves. Thosewho
had prognostic discussions with their physicians revised their
self-reported estimates downward by 17.2months, more toward
reality (months, not years), with nomore depression, sadness, or
anxiety, more advance directives, and better EOL care.32
Most PC practitioners use a standardized communication
approach to identify what the patient and family knows and
wants to know before wading into more sensitive and difficult
topics, such as prognostic awareness and delivering bad news.
We have found a temporary tattoo on the inner forearm that is
visible to theoncologistoradvancepracticenursetobehelpful in
remembering a way to get started with difficult conversations33
(Fig 1). After reviewing the four questions and getting to know
the patient and assessing family understanding and goals, it is
easier todomotivational interviewing: “You aredoingOKnow,
but have you thought about a time in the futurewhen youmight
be sicker, and need an advance directive or living will?”
A simple technique for oncologists to use is to address
understanding and prognosis after any scan that shows pro-
gressive disease. A new study found that only four of 64 on-
cologist discussions about scan results had frank prognosis
discussions. The authors suggested adding the question,
“Would you like to talk about what this means?” to allow the
patient some control aswell as to obtain permission to disclose
crucial information.34
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Using and responding to formal assessment by using
standard tools is usually a first step for the PC team or the
oncology team to get to know the patient. Starting with
symptoms is safe. Symptom assessment scales were used in
used in nearly all trials and can help identify how the patient
and family are coping. The Edmonton Symptom Assessment
System is a simple tool thatmeasures nine common symptoms
that are experienced by patients with cancer and can be com-
pleted in 5 minutes,35 although all available tools—Memorial
Symptom Assessment Scale, MD Anderson Symptom
Table 2. The Components of TEAM-Based Palliative Care
Component In the Trials What Is Known
Time A structured palliative care visit of at least 1 extra hour per
month; repeated at regular intervals (ie, monthly); not
once
These assessments can be conducted by a physician or
advanced practice nurse with specific training in
conducting such assessments
Education Structured, prospective, and recurrent discussions about
symptoms, goals, and preferences for care, prognosis
understanding, advance care planning, and
communication with the health care team
Education that is done prospectively and regularly, rather
than during a crisis is more effective
Usual topics include, on a recurring basis:
Medically appropriate options for treatment; patients
should know they have or have not left any medical
stones unturned; this is best done by listing the
treatments used and their outcomes, especially with
recurrent disease; if appropriate, reinforce patient and
family work as advocates.
Advance care planning; durable power of attorney or proxy
is not sufficient to change care patterns; a living will or
advance directive is needed21
Use of hospice for best possible care, and arranging
a hospice information visit once it is evident the disease
is going to take theperson’s life,with3-6months to live
or even longer
Assessment Formal assessments for:
Symptoms (ESAS, MSAS-C, CAPC rounding tool);
Spirituality (FICA, or “Are you a religious or spiritual
person?”);
Distress (Distress Thermometer, others)
Psychosocial (PHQ-2)
Caregiver strain
It is not sufficient to just ask “How are you?”; patients and
families are sometimes reluctant to share their
problems for fear that nothing can be done, or that it is
not in the clinician’s remit, the oncologist will stop
treating their cancer or theywill be labeleda complainer
After these formal symptom assessmentsmove onto goal
setting
We use questions such as:
How do you like to get medical information?
What is your understanding of your disease?
What is important to you?
What are you hoping for?
Have you thought about a time when you might become
sicker, such that you would need and advance directive
or living will? (some motivational interviewing)
We have incorporated this into a temporary tattoo that
gives oncologists a script to start the most difficult
discussions (Fig 1)
If progressive disease is evident, it is time to revisit goals of
care, prognosis understanding, and advance care
planning
Management By set protocols and an interdisciplinary team (APNs, social
workers, chaplains, doctors)
Interdisciplinary care and referralswere commonelements
of all studies
Givingpeopleknowledgeof their realisticoptionsandaplan
of action was shared across all the studies
An oncology office that does not have established social
work or chaplain ties should develop them,much as we
develop ties with surgeons or radiation oncologists
Abbreviations: APN, advance practice nurse; CAPC, Center to Advance Palliative Care; ESAS, Edmonton Symptom Assessment Scale; FICA, Faith and Belief,
Importance, Community, Address in Care; MSAS-C, Memorial Symptom Assessment Scale Condensed; PHQ-2, Patient Health Questionnaire-2.
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Inventory—work.36 Whereas oncologists may believe that
spiritual assessment is not part of their described medical as-
signment, 87% of patients with cancer want us to know their
spiritual needs, yet only 6%ofpatientswere ever asked.Receiving
spiritual care from the medical team was associated with a
doubled use of hospice, and the number of patients who died in
the intensive care unit—a marker of poor quality of care—fell
from22% to 0%.37 Yet, as oncologists, we often fail at this task: In
our audit of care administered to patients with glioblastoma,
none had a formal outpatient symptom, spiritual, or coping
assessment, with a rare statement of prognosis. Perhaps as a
consequence, 37%of patientswere hospitalized in the lastmonth
of life for an average of 9 days, only 17% had any advance
directive in the chart, andnearly 40% received chemotherapy in
the last month of life.38 We hope to do better by using the
formal tools that have been used in randomized trials and
establishing thresholds and protocols for interventions and
referral.
Management by an interdisciplinary team was also a key
component of randomized trials. In one Australian trial for
patients receiving PC, a structured regular meeting of the
interdisciplinary team (IDT) with recommendations to the
primary care physician demonstrated significant improve-
ment compared with practitioner education, with 26% fewer
hospitalizations.39 Most practices will have some components
of the IDT inplace: Socialworkers, chaplains, advancepractice
and oncology nurses, psychologists, allied health profes-
sionals, and physicians. A key step is to identify patients who
are at risk for complications and discuss them at a weekly IDT
meeting to troubleshoot. Such forward thinking and antici-
patory care as calling patients the day after a newchemotherapy
regimen has been a successful technique used by oncology
medical home models, which has led to reduced hospitaliza-
tions and lower costs.
We do not yet know which components of the multidisci-
plinary team are essential. When Muir et al40 delivered PC
in oncology offices with just a physician and advance practice
nurse, they showed better symptom management with a
21% decrease in symptom burden, an increase in oncologist
satisfaction (necessary for them to continue to work with on-
cologists), and an 87% increase in consultations in 2 years. They
saved each oncologist more than 4 weeks of time so that the
practice could do more regular oncology, and eased the on-
cologist’s burden as one strategy to avoid burnout. It is our
opinion that these services are essential, and in our experience,
providers, patients, and families greatly appreciate them, so we
incorporate themwithin thebudget.Mostpracticeshave financial
counseling available, but psychosocial counseling, such as social
workers or chaplains, are uncommon. Some nonreimbursable
services, such as chaplaincy or a social worker, may require
more formal testing before endorsement. US Oncology has
adopted the best practice model of appointing someone in
the office—usually a social worker or nurse—to review with a
patient advance care planningwithin the first visits of a diagnosis
of a life-limiting illness.Advance careplanningwas also increased
substantially,41 with some practices having completed advance
medical directives in up to 89% of patients.42 More evidence is
needed to guide US cancer care with regard to themost efficient,
yet effective, use of nonreimbursable support services.
The electronic health record may assist oncology practices
with some aspects of incorporating PC and oncology care. For
example, formal goals of care discussions can be formatted in the
note template to capture some of the practical parts of these
difficult conversations. This is similar to bringing up laboratory
values or radiographs on the computer screen; we bring up the
EPIC SmartPhrase to help remind and guide us in critical con-
versations, then type in the answers and print for the patient
informationpartofmeaningfuluse.Notesthatcontainthiscrucial
information are easy to send to referring health care practitioners
so that all can beon the samepage (Table 4). Such an approach is
nowbeingused inaphase I studyofpatients receivingconcurrent
care and seems to be a useful work-simplifying tool.
WHAT ARE SOMEOF THE CHANGES IN CARE THAT PC
INVOLVEMENT BRINGS?
Inadditionto thechanges insymptomsandqualityof lifenoted
in Table 1, PC involvement changes the course of care near
1.   How do you like to get medical information?  
2.   What is your understanding of your
      situation?
3.   What is important to you?
4.   What are you hoping for?
5.   Have you thought about a time when
      you could be sicker...Living Will or
      advance directive?
Fig 1. A temporary tattoo used as a script for starting difficult questions.
Available from Thomas J. Smith for $0.50 each.
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EOL.As amatter of course, we discuss the goals of care and set
up a hospice information visit when the patient has an esti-
mated prognosis of 6 months, the current timeframe sug-
gested by ASCOUniversity. If the PC team sees the patient as
an inpatient, the 30-day readmission rate is cut from 15% to
10%. If, during that consultation, we have the goals of care
discussion, the 30-day readmission rate is decreased from10%
to approximately 5%.43 Similar results were observed in a
hospital–hospice partnership with a five-fold reduction in
30-day readmission (1% v 5%).44
PC involvement gets more people to hospice and for
longer. If the PC team saw patients who were eligible for
hospice, 57%went homewith hospice. If the PC team did not
see them because the consultation was blocked by the
Table 3. Palliative Care Intervention Domains
Domain Elements Key Points
Therapeutic relationship Introducing the role of palliative care
Understanding the patient and caregiver
experience
Building trust with the patient and caregiver
Developastrong therapeutic relationshipwithpatientsand
caregivers
Learn about the values, life goals, and experiences of
patients and their caregivers, both before and after
cancer diagnosis
Develop trust and credibility with patients and caregivers
by providing reassurance and outlining parameters of
communication
Assessment and treatment
of patient symptoms
Preparing for symptoms
Assessing and treating symptoms
Coordinating symptom management with the
primary team
Providing referral for symptom management
Clarify the symptoms the patient will likely experience and
offer reassurance about the methods for reporting and
treating symptoms
At every visit, elicit existing and new symptom concerns
with emphasis on common symptoms (nausea, pain
and mucositis, fatigue, sleep disturbances,
constipation, diarrhea, anxiety, and depression)
Maintain ongoing, effective communication with other
clinicians to define mutual collaboration and work
within their preferred practice patterns
Emphasizea teamapproachtocareby referring tospecialty
care, mental health, alternative medicine, and spiritual
support as needed
Managing patients and
caregivers expectations
Reviewing in detail the expected illness
trajectory during the illness
Ensuring accurate expectations throughout
treatment
Enhancing patients’ and caregivers’
understanding and acceptance of the illness
Address early on patients and caregivers’ concerns about
the trajectory of illness and treatment adverse effects
Recognize that illness acceptance involves cognitive,
emotional, and behavioral elements and offer a safe
venue for patients and caregivers to ask questions
about their disease and treatment options
Coping with illness and
treatment
Reviewing and validating prior coping efforts
Discussing and advocating for different
methods of coping
Supporting caregiver coping
Providing referral for additional support
Recognize that patients and caregivers bring their own
expertise in copingwith thecurrent circumstanceon the
basis of prior experiences
Introduce strategies to help improve adjustment (eg,
behavioral, cognitive, and spiritual approaches;
accepting illness while maintaining hope; social
support)
Bolster caregiver coping by assessing burden, enhancing
their communication with patients, and recommending
additional support
Involve other members of the team for patients and
caregivers who may be experiencing severe distress
(eg, social work, psychology, chaplaincy)
NOTE. Modified from El-Jawahri et al17 and Temel et al.4 These were used by the palliative care specialist to guide the intervention. The oncologist can
adapt as needed.
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attending physician or came too late, only 27% went home
withhospice.45 Patients who received a PC team consultation
were 3.24 times more likely to be discharged to hospice
(P, .001), 1.52 times more likely to be discharged to a nursing
facility, and 1.59 times more likely to be discharged home
with services (P , .001).46 In New York Medicaid patients,
referrals to hospice increased more than 10-fold if the PC
team saw them.47 Going home with hospice means a 5%
Table 4. Goals of Care Discussion Template for EPIC, Cerner, or Other Electronic Medical Records
How do you like to get medical information?
Full or something else?
How about prognosis?
What is your understanding of your situation?
What is important to you?
What are you hoping for?
If the disease is growing, acknowledge that not all things have a medical fix
Ask if the patient would like to discuss what the scan findings mean?
List the prior treatments and response to give the patient a record of what was done; it may be important for families to leave nomedical stones unturned
Explore if the patient is eligible for clinical trials
Advance care planning
Do you have a will? (safe starter question)
Do you have a living will, advanced directive, or portable orders for life-sustaining treatments? (eg, POLST)
Are all of your providers aware of the wishes and proxy for your medical care that are stated in these documents?
Are documents readily available in your electronic health records and for all of your health care providers?
What does it say about CPR? (For patients imminently dying in the hospital of their cancer, the success rate of CPR is zero.)
Who do you want to make medical decisions, if you cannot?
Have you discussed this with her/him?
Are there spiritual issues to be settled?
Are there family issues to be settled?
Are there financial issues to be settled?
Have you met with hospice yet? (Plan for at least 3-6 months before death, which for most diseases is predictable; this really helps the transition if and
when hospice is needed.)
Have you thought about where you would like to be for your death, if and when?
Legacy work
Let’s start doing a life review—what you want people to remember about you.
And, what’s important to you?
What are you hoping for?
What do you want to accomplish in the time you have?
Living day to day
Exercise
Diet
Other instructions
How to call or reach me
Office
Days
Nights
Cell
E-mail
NOTE. Fill in as you interview on the screen, then print for the patient and family. It can be done on several visits and updated as the situation changes.
Abbreviation: POLST, Physician Orders for Life-Sustaining Treatment.
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30-day readmission rate versus a 25% rate for matched pa-
tients who did not go home with hospice.48
If PC is providedwith anoutpatient evaluation in the clinic,
the length of stay in regular hospice is increased from 15 to
24 days (P, .001).49 In one cancer center, if the PC team saw
the patient more than 1 month before death, the patterns of
care changed, with fewer EOL hospitalizations and $6,687 in
lower health systemcosts.50 From the pioneering study in lung
cancer by Temel, PC was associated with increased hospice
length of stay, lower daily costs, and equal costs despite living
2.7-months longer.5
Hospice, in turn, improves care51 and likely improves
survival.52,53 In one study, longer survival was associated with a
3.74-fold-lower likelihood to have high EOL care costs,54 and
Medicare data show that hospice saves $8,700 per patient.55
Oncologists can improve their performance with hospice
lengthofstaybymakingitaqualityassuranceissue.Constructive
feedback tooncologists that compares themwith theirpeers and
national averages for hospice length of stay led to a doubling of
hospicelengthofstaywithin1year, from19.7daysto39.6days.56
DISCUSSION
Specialist-based PC—initiated soon after a cancer
diagnosis—demonstrates improvements in quality of life,
mood, symptoms, and, at times, survival. These data are strong
for beginning such care as an outpatient, although the in-
troduction of PCprinciples in the emergency department or as
an inpatient has demonstrated positive outcomes as well. An
oncologist would not wait to use trastuzamab in patients with
human epidermal growth factor receptor 2–positive breast
cancer until the eighth randomized trial showed exactly which
regimen was absolutely the best. Immediately after those
landmark studies, we adopted the methods used in these
clinical trials that demonstrated so much benefit and have
beenmodifying our protocols as new data become available. It
is time to do the same with concurrent PC.
It is critical to distinguish PC from hospice care, the most
common subtype of PC familiar to most oncologists (Box 1).
We are still surprised how frequently we hear, “Oh, she’s not
ready for palliative care yet.” Hospice care is administered to
those who have no curative options and who have less than
6 months to live, if the disease process runs its natural course,
with proven benefits as described above. PC can and should
be provided with concurrent cancer-directed treatment on
the basis of need rather than prognosis. Despite the well-
established benefits, only approximately one half of all pa-
tientswho are dying of cancer are comanaged by hospice, and
at least one third use hospice for less than 1 week, amarker of
poor quality of care.
A compelling business case—outlined in the ASCO
guidelines—can bemade for the incorporation of PC to reduce
costs by improving the quality of care that people receive near
EOL to what they actually want, if those wishes are discerned.
Every study, to date, has shown that inpatient PC consultations
BOX 1. Distinguishing Hospice From Palliative Care
Hospice Care
Hospice is a type and philosophy of care that focuses on the palliation of a terminally ill patient’s symptoms by providing
care, not curing.
It is used when there are no longer curative options or reasonable options.
In the United States, hospice care is generally restricted to those who have less than 6 months to live, and must cover all
expenses with per diem payment of about $150.
Palliative Care
“Palliative care is specialized medical care for people with serious illness. This type of care is focused on providing patients
with relief from the symptoms, pain, and stress of a serious illness—whatever the diagnosis. The goal is to improvequality of
life for both the patient and the family.
Palliative care is provided by a team of palliative care doctors, nurses, and others who work together with a patient’s other
doctors to provide an extra layer of support. It is appropriate at any age and at any stage in a serious illness, and can be
provided together with curative treatment.”
– Diane Meier, MD, Director, Center to Advance Palliative Care57
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improve care andwith equal or lower costs.58-61 Such strategies
will be essential to make room in the current system for ever-
increasing care costs but that were never the intent of PC.
In summary, oncologists can and must learn to adopt the
techniques used in the trials of specialty PC concurrent with
usual oncology care, just as we learned to administer nivo-
lumab when the clinical trial evidence was compelling. The
TEAM approach is a good way for oncologists to start in-
corporating these techniques.
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